BBH - VanEck Vectors Biotech ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
129.21
-0.12 (-0.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close129.33
Open129.05
Bid121.64 x 1400
Ask131.99 x 1300
Day's Range128.67 - 129.63
52 Week Range111.36 - 136.83
Volume7,047
Avg. Volume18,542
Net Assets462.64M
NAV128.64
PE Ratio (TTM)N/A
Yield0.53%
YTD Return3.23%
Beta (3y)1.44
Expense Ratio (net)0.35%
Inception Date2011-12-20
Trade prices are not sourced from all markets
  • Considering Allergan’s Q2 2018 Revenue Trend
    Market Realistyesterday

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.

  • What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
    Market Realist10 days ago

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.

  • Bluebird Bio Misses Analysts’ Estimates in Q2 2018
    Market Realist15 days ago

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.

  • Investopedia16 days ago

    Adding Biotech ETFs to Your Portfolio

    As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.

  • What Analysts Recommend for Bluebird Bio Stock
    Market Realist18 days ago

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter. Of the 21 analysts tracking Bluebird Bio, five recommend “strong buy,” nine recommend “buy,” six recommend “hold,” and one recommends “sell.” 

  • Shire’s Q2 2018 Earnings Beat Analyst Estimates
    Market Realist18 days ago

    Shire’s Q2 2018 Earnings Beat Analyst Estimates

    Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018, compared to estimates for EPS of $3.67 on revenues of $3.8 billion.

  • ETF Trendslast month

    Biotech ETFs Climb on Biogen’s Promising Clinical Trial

    Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq ...

  • Top-Ranked Sector ETFs to Buy for Q3
    Zacks2 months ago

    Top-Ranked Sector ETFs to Buy for Q3

    These sector ETFs have a Zacks Rank #1 or 2 and are likely to outperform ahead.

  • What Drove Ionis’s Revenue in Q1
    Market Realist3 months ago

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.

  • BlueBird Bio Stock Jumps over 6% on May 17
    Market Realist3 months ago

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.

  • Allergan Reports Growth in 1Q18 Revenues
    Market Realist3 months ago

    Allergan Reports Growth in 1Q18 Revenues

    Headquartered in Ireland, Allergan (AGN) develops, manufactures, and commercializes pharmaceutical products and devices, as well as biologic products. On April 30, Allergan reported 2.8% revenue growth to ~$3.7 billion in 1Q18, compared to revenues of ~$3.6 billion in 1Q17. The chart below shows Allergan’s revenues since 1Q17.

  • Allergan’s 1Q18 Earnings: Analysts’ Estimates
    Market Realist4 months ago

    Allergan’s 1Q18 Earnings: Analysts’ Estimates

    Pharmaceutical giant Allergan (AGN) is set to release its 1Q18 earnings on April 30. Wall Street analysts estimate that the company could report earnings per share (or EPS) of $3.36 on revenues of $3.6 billion for 1Q18.

  • What’s Ionis Pharmaceuticals’ Valuation in March 2018?
    Market Realist5 months ago

    What’s Ionis Pharmaceuticals’ Valuation in March 2018?

    How Ionis Pharmaceuticals Is Positioned in 2018A look at Ionis Pharmaceuticals

  • A Look at Incyte’s Valuation in March 2018
    Market Realist5 months ago

    A Look at Incyte’s Valuation in March 2018

    Who’s Watching Incyte Corporation in March 2018?Incyte Corporation

  • The 4 Top Biotech ETFs
    Motley Fool5 months ago

    The 4 Top Biotech ETFs

    Investing in biotechnology has been very lucrative lately, and these funds can help you tap into the industry's success.

  • Gilead Sciences: Analysts’ Estimates after 4Q17
    Market Realist5 months ago

    Gilead Sciences: Analysts’ Estimates after 4Q17

    What Could Drive Gilead Sciences' Valuation in March?

  • 4 ETFs Set to Surge Amid Q4 Earnings
    InvestorPlace7 months ago

    4 ETFs Set to Surge Amid Q4 Earnings

    The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter. The S&P 500 index is anticipated to see earnings growth of 9.2% and revenue growth of 7%. The market is also at record levels, scaling series of highs at the start of the year.Source: Shutterstock

  • A Look at Ionis’s 3Q17 Revenue Stream
    Market Realist7 months ago

    A Look at Ionis’s 3Q17 Revenue Stream

    What's the Word on Ionis Pharmaceuticals This January?

  • How Was Incyte’s Revenue Stream in 3Q17?
    Market Realist7 months ago

    How Was Incyte’s Revenue Stream in 3Q17?

    As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.

  • Business Wire8 months ago

    VanEck Announces Yearend Distributions for VanEck Vectors Equity ETFs

    VanEck announced today the following 2017 annual distributions per share for its VanEck Vectors® equity exchange-traded funds.

  • Business Wire9 months ago

    VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs

    VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.

  • Market Realist11 months ago

    Benefitting from IBB’s Lower Expense Ratio

    The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.

  • Market Realist11 months ago

    How Gilead’s HIV and HBV Portfolios Performed in 2Q17

    Gilead Sciences' (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.

  • Investors getting back into M&A : York Capital co-CEO
    CNBC Videos10 months ago

    Investors getting back into M&A : York Capital co-CEO

    Daniel Schwartz, York Capital Management co-CEO, weighs in on the strength of the M&A market and where he sees the biggest opportunities, including biotechnology and the telecom industry.